Chlorogenic Acid

SKU: orb1304998

Description

Chlorogenic Acid

Research Area

Epigenetics & Chromatin, Immunology & Inflammation, Infectious Disease & Virology, Metabolism Research, Signal Transduction

Key Properties

• CAS Number: 327-97-9
• MW: 354.31
• Purity: 99.20%
• Formula: C₁₆H₁₈O₉
• SMILES: O(C(C=CC1=CC(O)=C(O)C=C1)=O)[C@@H]2C[C@@](C(O)=O)(O)C[C@@H](O)[C@H]2O
• Target: Influenza Virus,HIF/HIF Prolyl-Hydroxylase,Antibacterial,Endogenous Metabolite,Reactive Oxygen Species
• Solubility: Ethanol:66 mg/mL (186.28 mM);DMSO:237 mg/mL (668.91 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:5 mg/mL (14.11 mM);H2O:10 mg/mL (28.22 mM)

Bioactivity

• Target IC50:
  HBV DNA:1.2 ± 0.4 μM|SW48 cells:353 μM|HSV1:15.3 μg/mL (EC50)|HeLa cells:375 μM|HCT116 cells:367 μM|BALB/3T3 cells:> 280 μM|Caco-2 cells:758 ± 19.09 µM (EC50)
• In Vivo:
  METHODS: To assess the anti-obesity effects, Chlorogenic acid (150 mg/kg) was administered by gavage to ICR mice on a high-fat diet model (HFD) once daily for six weeks. RESULTS: Administration of Chlorogenic acid significantly promoted weight loss, decreased plasma lipid levels, and altered mRNA expression of genes related to adipogenesis and lipolysis in adipose tissue.
• In Vitro:
  METHODS: Human colorectal cancer cells Caco-2 were treated with Chlorogenic acid (50-1000 µM) for 24 h and cell viability was measured by MTT assay. RESULTS: Proliferation of Chlorogenic acid-treated cells was significantly reduced, starting at the lowest tested concentration (50 µM), with an EC50 of 758 ± 19.09 µM. METHODS: Mouse mammary carcinoma cells 4T1 were treated with Chlorogenic acid (50-200 µM) for 24 h to enable detection of apoptosis by Flow cytometry. RESULTS: In the early stage, the level of apoptotic cells (Annexin V+/PI-) increased significantly from 1.14% to 0.04%, 34.56%, 40.9% and 37.46% with increasing concentrations of Chlorogenic acid (0, 50, 100, 150 and 200 µM, respectively). Whereas, in the late phase, when the cells were treated with Chlorogenic acid, the apoptotic cell ratio (Annexin V+/PI+) significantly increased from 2.34% to 2.08%, 13.45%, 17.7% and 29.06%, respectively.

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

NSC 407296, inhibit, Influenza Virus, InfluenzaVirus, NSC407296, NSC-407296, EndogenousMetabolite, Endogenous Metabolite, HIF, HIFs, HIFProlylHydroxylase, HIF ProlylHydroxylase, HIF Prolyl-Hydroxylase, HIF/HIF Prolyl-Hydroxylase, HIF/HIF ProlylHydroxylase, HIF-PH, HIF/HIFProlylHydroxylase, Heriguard, Inhibitor, Hypoxia-inducible factors, Chlorogenic Acid, Bacterial, 3-O-Caffeoylquinic acid, Reactive Oxygen Species, ReactiveOxygenSpecies

Compound Identifiers

PubChem CID

9476